Oncology News | pharmaphorum

News

FDA appoints veteran Pazdur to replace Tidmarsh

The FDA has steadied the ship at CDER by naming veteran regulator Richard Pazdur as director, although he was reportedly reluctant to take the job.

News

enGene's president and chief executive, Ron Cooper

Trial sets up filing for enGene bladder cancer gene therapy

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

Daiichi Sankyo launches its STING operation against cancer

Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

News

Eisai settles Lenvima patent dispute with Torrent Pharma

A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.

News

AZ's Q3 sales reach record $15bn, but it holds guidance

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.

FDA appoints veteran Pazdur to replace Tidmarsh

Trial sets up filing for enGene bladder cancer gene therapy

Daiichi Sankyo launches its STING operation against cancer

Braveheart, AAVantgarde rounds head recent biofinancings

Eisai settles Lenvima patent dispute with Torrent Pharma

AZ's Q3 sales reach record $15bn, but it holds guidance

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks